HCV NS3 protease inhibitors

1. A compound of formula (I):

wherein:

is one or more rings selected from the group consisting of:

R 1 is selected from the group consisting of —CO 2 R 10 and —CONR 10 SO 2 R 6 ;

R 2 is —CH═CH 2 ;

R 3 is C 1 -C 6 alkyl;

R 6 is C 3 cycloalkyl;

Y is selected from the group consisting of —OC(O)—;

Z is a direct bond;

M is selected from the group consisting of C 1 -C 12 alkylenes and C 2 -C 12 alkenylenes, wherein said M is substituted with 1 to 2 substituents F independently selected from the group consisting of C 1 -C 8 alkyl and ═CH 2 ;

X is selected from the group consisting of —(CH 2 ) 0-3 O—, wherein is attached to —(CH 2 ) 0-3 if present; and

each R 10 is independently H.

2. The compound according to claim 1 , wherein M is selected from the group consisting of —CH═CH(CH 2 ) 5 , —(CH 2 ) 7 —, —CH 2 CH═CH(CH 2 ) 4 —, —(CH 2 ) 6 —, —CH═CH(CH 2 ) 4 —, —CH═CH(CH 2 ) 3 C(CH 3 ) 2 CH 2 —, —CH═CH(CH 2 ) 3 —, —(CH 2 ) 5 —, —CH═CH(CH 2 ) 3 —, —(CH 2 ) 4 —, —(CH 2 ) 3 —, —CH═CH(CH 2 ) 2 C(CH 3 ) 2 CH 2 —, —(CH 2 ) 4 C(CH 3 ) 2 CH 2 —, —C(═CH 2 )(CH 2 ) 5 —, —C(═CH 2 )(CH 2 ) 3 —, and —CH 2 CH═CH(CH 2 ) 3 —.

3. The compound according to claim 2 , wherein M is selected from the group consisting of

4. A compound selected from the group consisting of:

5. A pharmaceutical composition comprising an effective amount of the compound according to claim 1 , and a pharmaceutically acceptable carrier.

6. The pharmaceutical composition according to claim 5 , further comprising a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.

7. The pharmaceutical composition according to claim 5 , further comprising a second therapeutic agent selected from the group consisting of HCV protease inhibitors and HCV NS5B polymerase inhibitors.